Related Experiment Video
Updated: Jul 10, 2026

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice
Published on: February 3, 2012
Hepatitis C and kidney disease
P Coccoli1, P Esposito, B Cianciaruso
1Dipartimento di Medicina Clinica e Sperimentale, Cattedra di Gastroenterologia, Università Federico II, Napoli, Italy.
Insights
Hepatitis C virus (HCV) infection is linked to various kidney diseases, notably diabetic nephropathy and MPGN. This study found a significant association between HCV and diabetes in patients with chronic kidney disease.
Area of Science:
- Nephrology
- Hepatology
- Virology
Background:
- Hepatitis C virus (HCV) infection is a known cause of kidney diseases like MPGN, MGN, and FSGN.
- The prevalence of HCV in patients with chronic nephropathy, particularly in the predialytic phase, requires further investigation.
Purpose of the Study:
- To determine the frequency of HCV infection in patients with predialytic chronic nephropathy.
- To identify kidney disease types associated with HCV in this patient cohort.
- To explore the relationship between HCV infection and diabetes mellitus.
Main Methods:
- 340 patients with chronic renal insufficiency (CRI) were screened for anti-HCV antibodies.
- HCV RNA testing by PCR was performed on positive subjects.
- Biohumoral parameters, including transaminases, and co-existing conditions like diabetes and HBsAg were monitored.
Main Results:
- HCV RNA was detected in 46 (13.5%) of the 340 subjects.
- Diabetic nephropathy (23.9%) and MPGN (15.2%) were the most frequent kidney diseases in HCV-RNA positive patients.
- HCV infection showed a positive association with Type II diabetes mellitus (26% vs. 12.5%).
Conclusions:
- HCV infection is frequently associated with diabetic nephropathy and MPGN in predialytic chronic kidney disease patients.
- A notable association exists between HCV infection and diabetes mellitus.
- HCV in this cohort presented with mild liver disease, with only 9% showing cirrhosis evidence.
Abstract:
Hepatitis C virus (HCV) infection is often associated with kidney diseases such as membranoproliferative glomerulonephritis (MPGN), with and without cryoglobulinemia, membranous glomerulonephritis (MGN) or glomerulosclerosis (FSGN). The aim of our study was to determine the frequency of HCV with or without hypertransaminasemia in patients with chronic nephropathy in the predialytic phase. We tested 340 subjects with chronic renal insufficiency (CRI) from our hospital's nephrology outpatient clinic for anti-HCV antibodies. In positive subjects we tested for HCV RNA by PCR method, monitoring, for at least 4 months, common biohumoral parameters including transaminases (AST, ALT). Of the 340 subjects, 46 (13.5%) were positive for HCV RNA, and 8 of these (17%) showed constant alteration of transaminases. HBsAg was found in 8 of the total study population (2.3%), and none of these showed altered transaminases. Type II diabetes mellitus was found in 26% (12/46) of the HCV-RNA positive patients, and in only 12.5% (37/294) of the negative ones. The kidney diseases we found in the 46 HCV-RNA positive patients were: diabetic nephropathy in 11 (23.9%), MPGN in 7 (15.2%), MPGN + cryoglobulinemia in 2 (4.3%), interstitial nephropathy in 4 (8.7%), IgA mesangial GN in 3 (6.5%), hypertensive nephropathy in 2 (4.3%), focal and segmental GN in 1 (2.2%), urologic disease in 4 (8.7%), other (hematological, genetic, iatrogenic) in 3 (6.6%), unknown in 9 (19.6%). Our data show that the most frequent kidney diseases associated with HCV infection were diabetic related nephropathy and MPGN with and without cryoglobulinemia. HCV infection had a positive association with diabetes. It is interesting to note that in this study population the hepatitis C concomitant to kidney disease was unusually mild: only 4 of the 46 subjects (9%) showed clinical, biohumoral and ultrasound evidence of cirrhosis.
Related Concept Videos
Hepatitis
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic Kidney Disease II: Clinical Manifestations
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Kidney Transplant I: Introduction
Chronic Kidney Disease I: Introduction
